COMPARISON OF THE SAFETY AND IMMUNOGENCITITY OF LYOPHILIZED IMVAMUNE® (1X10 8 TCID 50 ) VERSUS LIQUID FORMULATION IMVAMUNE® (1X10 8 TCID 50 ) ADMINISTERED BY THE SUBCUTANEOUS ROUTE AND A LOWER DOSE LIQUID FORMULATION IMVAMUNE® (2X10 7 TCID 50 ) ADMINI STERED BY THE INTRADERMAL ROUTE IN HEALTHY VACCINIA - NAÏVE INDIVIDUALS (DMID PROTOCOL NUMBER 09 - 0002).